ACTUATE THERAPEUTICS, INC. (ACTU) - Dilution Analysis

10-Q filing | 23.5M shares outstanding

8-K filing: Actuate Therapeutics, Inc. entered into an Underwriting Agreement with Lucid Capital Markets, LLC for an underwritten offering of 2,142,858 shares of common stock at a price of $7.00 per share, with an over-allotment option for an additional 321,428 shares, expected to close on September 11, 2025. ($15.0M proceeds)

S-3 filing: Actuate Therapeutics, Inc. is offering an aggregate amount of $250 million of any combination of common stock, preferred stock, and debt securities.

10-Q filing | 19.6M shares outstanding

S-1 filing: This prospectus relates to the resale from time to time by the selling stockholders identified herein of up to an aggregate of 1,332,994 shares of common stock and shares of Common Stock issuable upon the exercise of warrants.

8-K filing: Actuate Therapeutics, Inc. entered into a securities purchase agreement for a private placement, agreeing to issue 666,497 shares of common stock at $7.00 per share and warrants to purchase up to 666,497 shares with an exercise price of $7.00, with the Private Placement expected to close on or before June 30, 2025. ($4.67M proceeds)

10-Q filing | 19.5M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 3,904,374 shares of common stock by B. Riley Principal Capital II, LLC, with the company potentially receiving up to $50,000,000 in aggregate gross proceeds under a common stock purchase agreement.

10-K filing | 19.5M shares outstanding

10-Q filing | 19.5M shares outstanding

10-Q filing | 19.5M shares outstanding

S-1/A filing: Actuate Therapeutics, Inc. is offering 2,950,000 shares of common stock in an initial public offering, with an estimated price between $8.00 and $10.00 per share, and has granted the underwriters an option to purchase up to an additional 442,500 shares.

S-1/A filing: Actuate Therapeutics, Inc. is offering 2,777,778 shares of common stock in its initial public offering, with an estimated price between $8.00 and $10.00 per share, and has granted the underwriters an option to purchase up to an additional 416,666 shares.

S-1/A filing: Actuate Therapeutics, Inc. is offering 5,555,556 shares of common stock in an initial public offering, with an estimated price between $8.00 and $10.00 per share.

S-1/A filing: Actuate Therapeutics, Inc. is offering 5,555,556 shares of common stock in its initial public offering, with an estimated price between $8.00 and $10.00 per share. The underwriters have an option to purchase up to an additional 833,333 shares.

S-1/A filing: Actuate Therapeutics, Inc. is offering 5,555,556 shares of common stock in an initial public offering, with an estimated price between $8.00 and $10.00 per share and an option for underwriters to purchase an additional 833,333 shares.

S-1 filing: Actuate Therapeutics, Inc. is offering shares of its common stock in an initial public offering, with an estimated IPO price between an unspecified range. The company has applied to list its common stock on the Nasdaq Capital Market under the symbol "ACTU".